Developing new cancer drugs is expensive. Before a new cancer drug goes to trial it is developed for a year or two, and costs around $100 million. Also, 95% of cancer drugs fail in clinical trials meaning there are lots of misses before a hit. Berg, a biotech startup, wants to harness artificial intelligence to develop the next generation of cancer treatments. The company has created BPM 31510, the first cancer drug developed by artificial intelligence being tested in clinical studies. When cancer spreads mitochondria that usually tell damaged cells to die go crazy, and spread. BPM 31510 focuses on the mitochondria, and tries to restore a normal cell’s dying process. Though BPM 31510 is still in early trial stages, it could hint at how future drugs will be developed.
The next frontier in medicine: drugs designed by artificial intelligence
More of Today's Solutions
A daycare built a ‘forest floor’, and it changed kids’ immu...
Time in nature is valuable for children’s physical and mental health, so one daycare in Finland decided to invest in a playground that replicated ...
Read MoreThis 30-minute training can help teenagers’ response to stress
Many successful people live by the expression “in every tragedy, there is an opportunity.” It turns out that the same kind of thinking can ...
Read MoreThe ongoing success of the 4-day workweek: a year in, companies share insights
Nearly 61 British businesses made the historic switch to a four-day workweek in 2022, setting in motion a cascade of beneficial effects that are still ...
Read MoreBartering is back: how to trade your skills and goods without spending a dime
BY THE OPTIMIST DAILY EDITORIAL TEAM In a world where we’re used to swiping cards and tapping phones to pay, it might seem old-fashioned ...
Read More
